Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) FCF Margin (2016 - 2025)

Historic FCF Margin for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to 217.21%.

  • ImmunityBio's FCF Margin rose 14294400.0% to 217.21% in Q3 2025 from the same period last year, while for Sep 2025 it was 393.43%, marking a year-over-year increase of 55271200.0%. This contributed to the annual value of 2700.06% for FY2024, which is 611811300.0% up from last year.
  • Latest data reveals that ImmunityBio reported FCF Margin of 217.21% as of Q3 2025, which was up 14294400.0% from 306.06% recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's FCF Margin registered a high of 217.21% during Q3 2025, and its lowest value of 730550.0% during Q1 2022.
  • In the last 5 years, ImmunityBio's FCF Margin had a median value of 48598.56% in 2021 and averaged 115189.8%.
  • As far as peak fluctuations go, ImmunityBio's FCF Margin crashed by 2000000000bps in 2022, and later surged by 2000000000bps in 2023.
  • Quarter analysis of 5 years shows ImmunityBio's FCF Margin stood at 21036.41% in 2021, then plummeted by -614bps to 150216.44% in 2022, then soared by 41bps to 88651.8% in 2023, then surged by 99bps to 1155.39% in 2024, then surged by 81bps to 217.21% in 2025.
  • Its FCF Margin stands at 217.21% for Q3 2025, versus 306.06% for Q2 2025 and 526.89% for Q1 2025.